Circulating anti-pericyte autoantibodies are present in Type 2 diabetic patients and are associated with
R C Nayak1, C D Agardh, M G K Kwok
1Department of Ophthalmology, Tufts University School of Medicine, Tufts Center for Vision Research and New England Eye Center, Tufts-New England Medical Center (Box450), 750 Washington Street, MA 02111, Boston, USA. rnayak@tufts-nemc.org
Aims/Hypothesis:
This study aims to determine the prevalence of anti-pericyte autoantibodies in Type 2 diabetes and to characterize these autoantibodies as new markers of disease activity in diabetic retinopathy.
Methods:
A total of 299 patients with Type 2 diabetes participated in this study. Retinopathy was assessed by 7-field stereo fundus photography and was graded according to the ETDRS scale. Serum anti-pericyte autoantibodies were detected by immunofluorescence on tissue cultured bovine retinal pericytes.
Results:
The prevalence of anti-pericyte autoantibodies in Type 2 diabetic patients was 54% and was approximately equal in men and women. The prevalence was approximately 55% with retinopathy at grades from 10 to 53. At grades above 53 the prevalence declined to 23% ( p<0.0001). The highest prevalence by duration of diabetes, 70%, was found at 0 to 5 years and the lowest, 25% at more than 25 years duration ( p<0.0001).
Conclusion/Interpretation:
Anti-pericyte autoantibodies are present at high prevalence in Type 2 diabetes. Their presence during earlier stages of retinopathy could be due to a reaction with antigens expressed by "activated" pericytes. The decline in antibody prevalence in advanced retinopathy could mark pericyte loss and progression to an angiogenic retinal milieu.
Related Concept Videos
Diabetes Mellitus: Type 2 and Gestational
Type I Diabetes I: Introduction
Type I Diabetes II: Pathophysiology
Type II Diabetes II: Pathophysiology
Diabetic Retinopathy
Diabetic Nephropathy


